Intrarosa

During, and after, menopause >50% of women experience symptoms of vulvovaginal atrophy, which includes vaginal dryness, itching/burning sensation and pain during sexual intercourse. Intrarosa is a medicine used to treat postmenopausal women with moderate to severe symptoms of vulvar and vaginal atrophy. In these women, the wall of the vagina and surrounding tissues become thinner and can cause symptoms such as dryness, irritation and soreness around the genital area, and painful sexual intercourse.

Intrarosa contains the active substance prasterone (also known as dehydroepiandrosterone, DHEA) which is biochemically and biologically identical to endogenous human DHEA.

DHEA is an inactive precursor steroid, which will be converted to estrogens and androgens (eg testosterone), once taken up into vaginal cells. Intrarosa is therefore different than local estrogenic treatments (eg Vagifem®) through the dual action of estrogens and androgens.

Links to product sites:

Intrarosa® (prasterone), 6.5 mg pessary. Rx, EF.

ATC code: G03XX01

Therapeutic indications: Intrarosa is indicated for the treatment of vulvar and vaginal atrophy in postmenopausal women having moderate to severe symptoms.

Dosing: The recommended dose is 6.5 mg prasterone (one pessary) administered once daily, at bedtime. The product can be administered with or without the enclosed applicator.

Storage: Store below 30°C. Do not freeze.

Package information: blister packs with 28 pessaries

▼ This medicinal product is new and subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. For the treatment of postmenopausal symptoms, Intrarosa should only be initiated for symptoms that adversely affect quality of life. In all cases, a careful appraisal of the risks and benefits should be reassessed at least every 6 months and Intrarosa should only be continued as long as the benefit outweighs the risk. For full information regarding prescription and SPC (December 2019) please see www.fass.se